(ENXTBR:ARGX) shares closed at €671.80, with recent moves likely catching the eye of investors watching biotech valuations.

(NASDAQ:ARGX) used its presentation at the 44th JPMorgan Healthcare Conference to highlight what CEO Tim Van Hauwermeiren ...

In early January 2026, argenx reported preliminary full-year 2025 global product net sales of US$4.15 billion, outlined ...

Argenx has announced that the US Food and Drug Administration has accepted for priority review a supplemental biologics ...

Buying $100 In ARGX: If an investor had bought $100 of ARGX stock 5 years ago, it would be worth $253.74 today based on a price of $800.01 for ARGX at the time of writing.

AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving ...

Argenx (ARGX) stock gains as the FDA grants priority review to expand use of the company's blockbuster drug Vyvgart in myasthenia gravis. Read more here.

Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO ...

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19 ...

Argenx Se’s strong financial performance and bullish technical indicators are the primary drivers of its high stock score. The company’s robust revenue growth and strategic advancements in its ...

On January 13, 2026, argenx SE announced that the U.S. Food and Drug Administration accepted for priority review its supplemental Biologics License Application for intravenous VYVGART (efgartigimod ...